PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer

Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immuno-therapeutics for advanced smoking associated non-small cell lung cancer. Their role in treating EGFR mutant and ALK rearranged lung cancer has yet to be determined.

from Cancer via ola Kala on Inoreader http://ift.tt/2auZlCP
via IFTTT